Avelumab and Merkel Cell Carcinoma: Prognosis and Treatment Considerations

Legacy of General Health and Science Information

The Immunodeficiency Foundation has long served as a repository for general health and science information, documenting broad immunological principles and historical perspectives on disease management. Its archives traditionally emphasize foundational knowledge applicable across diverse clinical contexts, from infectious disease control to cancer immunology. This legacy of accessible, context-neutral health education provides a baseline understanding of how immune system modulation influences patient outcomes. Within this framework, the transition to occupational exposure concerns requires a focused shift. While the foundation’s resources address general immune function, contemporary pharmacovigilance data increasingly highlight specific therapeutic agents as potential risk factors in certain populations. Avelumab, a programmed death-ligand 1 inhibitor approved for Merkel cell carcinoma, represents a case where treatment exposure intersects with occupational health considerations. Patients receiving avelumab may face altered immune surveillance, raising questions about long-term carcinogenic risk in occupational settings where additional environmental exposures occur. This pivot from general health education to targeted exposure assessment underscores the need for integrated monitoring protocols. The foundation’s archival approach now accommodates queries that bridge therapeutic exposure and occupational risk, without venturing into mechanistic claims. Instead, it emphasizes the importance of longitudinal data collection for individuals with avelumab exposure, particularly those in industries with known carcinogen contact. Such vigilance aligns with the foundation’s mission to preserve actionable health information while adapting to emerging clinical realities.

Bridge to Avelumab and Merkel Cell Carcinoma

Building on the foundation's legacy of general health education, this section transitions to the specific context of avelumab, a therapeutic agent that has transformed the treatment landscape for Merkel cell carcinoma (MCC). Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic MCC, a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). This approval marked avelumab as the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The clinical presentation of MCC typically involves a rapidly growing, painless nodule on sun-exposed skin, often in older individuals. Diagnosis relies on histopathology and immunohistochemistry, revealing neuroendocrine differentiation. The disease is associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). MCC carries high rates of recurrence and mortality, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Clinical Evidence and Treatment Outcomes

The approval of avelumab for metastatic MCC was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200. In Part A of this study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab's mechanism of action involves blocking PD-L1, thereby preventing the inhibition of T-cell activity and enhancing the immune response against tumor cells. However, this immune activation can lead to immune-related adverse events (irAEs). Reported adverse effects include overactivation of the immune system, which may cause conditions such as sarcoidosis. A case report described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while irAEs can occur, they may be manageable without necessitating treatment discontinuation.

Risk Context and Prognosis for Refractory Disease

For patients who become refractory to avelumab, treatment options are limited. In Europe, approved systemic therapies for MCC are restricted to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, combined therapy with ipilimumab and nivolumab has shown activity. In a retrospective study at three German sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG further supported the use of ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study confirmed that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab currently approved by the U.S. Food and Drug Administration for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding risk considerations, the adequacy of warnings about avelumab and MCC is tied to its approved indication: avelumab is specifically indicated for metastatic MCC, and its prescribing information includes warnings about immune-related adverse events. However, the timeline between exposure and documented harm is variable. In the case of sarcoidosis reactivation, the adverse event occurred during treatment and was managed without discontinuation (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline to progression can vary, but approximately half of patients may progress during therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Prognosis for affected patients depends on response to treatment; those who respond to avelumab may experience durable benefits, while those who are refractory may have a poor prognosis, though subsequent therapies like ipilimumab plus nivolumab offer some hope (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, avelumab represents a significant advancement in the treatment of metastatic MCC, with a well-defined mechanism of action and a manageable safety profile. However, the risk of progression remains substantial, and ongoing research is needed to optimize sequential or combination therapies for refractory disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how does it work for Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It blocks PD-L1, preventing inhibition of T-cell activity and enhancing the immune response against tumor cells. It was approved for metastatic Merkel cell carcinoma based on the JAVELIN Merkel 200 trial.

What is the prognosis for patients with avelumab-refractory Merkel cell carcinoma?

For patients who become refractory to avelumab, treatment options are limited, but combined therapy with ipilimumab and nivolumab has shown activity. In a retrospective study, three out of five patients responded to this combination (https://pubmed.ncbi.nlm.nih.gov/33439294/). Prognosis depends on response; those who respond to avelumab may have durable benefits, while refractory patients may have a poor prognosis, though subsequent therapies offer some hope.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.